Xencor (NASDAQ:XNCR) Shares Gap Up to $26.05

Shares of Xencor, Inc. (NASDAQ:XNCR – Get Rating) gapped up prior to trading on Friday . The stock had previously closed at $26.05, but opened at $27.22. Xencor shares last traded at $27.02, with a volume of 60,940 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Mizuho restated a “buy” rating and issued a $59.00 target price on shares of Xencor in a report on Friday, February 10th. EF Hutton Acquisition Co. I restated a “buy” rating and issued a $42.00 target price on shares of Xencor in a report on Friday, February 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Xencor in a report on Monday, May 15th. StockNews.com started coverage on shares of Xencor in a research report on Thursday. They set a “sell” rating for the company. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of Xencor in a research report on Thursday, February 23rd. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Xencor currently has an average rating of “Moderate Buy” and an average price target of $45.00.

Xencor Trading Up 5.4 %

The firm has a market cap of $1.66 billion, a P/E ratio of -11.73 and a beta of 0.79. The business’s fifty day simple moving average is $27.82 and its 200-day simple moving average is $29.25.

Xencor (NASDAQ:XNCR – Get Rating) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.27). The business had revenue of $18.90 million for the quarter, compared to analysts’ expectations of $26.89 million. Xencor had a negative net margin of 142.32% and a negative return on equity of 19.41%. The company’s revenue was down 77.9% on a year-over-year basis. During the same period last year, the business earned $0.39 earnings per share. Analysts anticipate that Xencor, Inc. will post -2.99 earnings per share for the current year.

Insider Activity

In other news, VP Celia Eckert sold 2,462 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $31.42, for a total value of $77,356.04. Following the completion of the sale, the vice president now directly owns 37,687 shares of the company’s stock, valued at $1,184,125.54. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO John J. Kuch sold 919 shares of Xencor stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $31.54, for a total transaction of $28,985.26. Following the completion of the sale, the chief financial officer now owns 129,715 shares of the company’s stock, valued at $4,091,211.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Celia Eckert sold 2,462 shares of Xencor stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $31.42, for a total transaction of $77,356.04. Following the sale, the vice president now directly owns 37,687 shares of the company’s stock, valued at approximately $1,184,125.54. The disclosure for this sale can be found here. Insiders sold 23,740 shares of company stock valued at $739,628 over the last three months. Insiders own 4.23% of the company’s stock.

Institutional Investors Weigh In On Xencor

Large investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC boosted its holdings in Xencor by 364.8% in the third quarter. Quadrant Capital Group LLC now owns 2,180 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 1,711 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Xencor by 48.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,438 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 795 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Xencor during the 4th quarter worth about $73,000. Dark Forest Capital Management LP raised its position in shares of Xencor by 568.5% during the 1st quarter. Dark Forest Capital Management LP now owns 3,369 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 2,865 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Xencor by 203.0% during the 1st quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 3,005 shares during the last quarter. 98.99% of the stock is owned by hedge funds and other institutional investors.

About Xencor

(Get Rating)

Xencor, Inc is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions.